- Home
- IMAB vs AGL Comparison
IMAB vs AGL Comparison
Compare IMAB & AGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- AGL
- Stock Information
- Founded
- IMAB 2014
- AGL 2016
- Country
- IMAB United States
- AGL United States
- Employees
- IMAB N/A
- AGL N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- AGL Managed Health Care
- Sector
- IMAB Health Care
- AGL Health Care
- Exchange
- IMAB Nasdaq
- AGL Nasdaq
- Market Cap
- IMAB 394.2M
- AGL 443.4M
- IPO Year
- IMAB 2020
- AGL 2021
- Fundamental
- Price
- IMAB $4.39
- AGL $1.07
- Analyst Decision
- IMAB Strong Buy
- AGL Hold
- Analyst Count
- IMAB 6
- AGL 20
- Target Price
- IMAB $7.17
- AGL $2.75
- AVG Volume (30 Days)
- IMAB 1.7M
- AGL 6.2M
- Earning Date
- IMAB 11-02-2025
- AGL 11-04-2025
- Dividend Yield
- IMAB N/A
- AGL N/A
- EPS Growth
- IMAB N/A
- AGL N/A
- EPS
- IMAB N/A
- AGL N/A
- Revenue
- IMAB N/A
- AGL $5,901,182,000.00
- Revenue This Year
- IMAB N/A
- AGL N/A
- Revenue Next Year
- IMAB N/A
- AGL $6.21
- P/E Ratio
- IMAB N/A
- AGL N/A
- Revenue Growth
- IMAB N/A
- AGL 11.76
- 52 Week Low
- IMAB $0.60
- AGL $0.71
- 52 Week High
- IMAB $5.90
- AGL $6.08
- Technical
- Relative Strength Index (RSI)
- IMAB 59.97
- AGL 40.92
- Support Level
- IMAB $3.98
- AGL $1.11
- Resistance Level
- IMAB $4.51
- AGL $1.18
- Average True Range (ATR)
- IMAB 0.30
- AGL 0.07
- MACD
- IMAB 0.07
- AGL 0.01
- Stochastic Oscillator
- IMAB 89.30
- AGL 25.00
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.